Silicon Valley cancer diagnostics trailblazer, Guardant Health, is gearing up for an intense legal tussle as it appeals an adverse $83.4 million verdict handed down a day earlier in a high-stakes patent battle against a Seattle-based rival. Unanimous Blow in Wilmington, Delaware The seismic verdict, delivered in Wilmington, Delaware on Tuesday, concluded a gripping five-day
BOSTON & DAEJEON, South Korea (BUSINESS WIRE) #ADC Orum Therapeutics (“Orum”), a clinical-stage private biotechnology company pioneering Dual-Precision Targeted Protein Degradation (TPD² ™) and Targeted Protein Stabilization (TPS² ™), today announced that they have entered into a definitive agreement under which.
A California state appellate court has found that a lower court wrongly dismissed parts of a lawsuit challenging the constitutionality of a controversial DNA collection program operated by the Orange County District Attorney's Office, ordering the case to proceed to discovery.
Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases , which amended. | March 31, 2023
The generic drugmakers argued that the patents were invalid and unenforceable. They said in an August court filing that Gilead s patents covered "routine and predictable" variants of a "compound it.